Prostate Cancer Flashcards
What is the pathophysiology of prostate cancer?
Testosterone and dihydrotestosterone (DHT) are the major androgens (male hormones) in the adult male. Testosterone is produced by the testis and circulates in the blood. DHT is a testosterone derivative in the prostate gland. In some patients, the prostate grows very rapidly, leading to noncancerous high-grade prostatic intraepithelial neoplasia (PIN). This impairment of cellular regulation causes men to be at a higher risk for developing prostate cancer than men who do not have that growth pattern.
Many prostate tumors are androgen-sensitive. Most are adenocarcinomas and arise from epithelial cells located in the posterior lobe or outer portion of the gland. Of all malignancies, prostate cancer is one of the slowest growing, and it metastasizes in a predictable pattern. Common sites of metastasis are the nearby lymph nodes, and bones, although it can also metastasize to the lungs or liver. The bones of the pelvis, sacrum, and lumbar spine are most often affected.
What risk factors are associated with prostate cancer?
- Advanced age is the leading risk factor
- First-degree relative with the disease
- African American men
- Diet high in animal fat and dairy
What needs to be taught to the patient regarding prevention?
Teach men to eat a healthy, balanced diet, including decreasing animal fat (e.g., red meat) and the intake of dairy products. Also reinforce the need to increase fruits and vegetables—especially tomatoes, which are high in lycopene. Soy contains phytoestrogens that are thought to be helpful in reducing the risk for prostate cancer
What information should the nurse gather when obtaining history from the patient?
- Assess the patient’s age, race/ethnicity, and family history of prostate cancer.
- Ask about his nutritional habits, especially focusing on the intake of red meat and dairy products as a source of concern.
- Recognize that in early prostate cancer, there are often no signs or symptoms experienced by the patient.
- Assess whether the patient has existing or new problems with urinary elimination.
- Take a drug history to determine if he is taking any medication that could affect voiding.
- The first symptoms that the man may notice and report are related to bladder outlet obstruction (BOO), such as difficulty in starting urination, frequent bladder infections, and urinary retention.
- Ask about urinary frequency, hematuria (blood in the urine), and nocturia.
- Ask if he has had any pain during intercourse, especially when ejaculating.
- Inquire if he has had or currently has any other pain (particularly bone pain in the hips and legs), a symptom associated with advanced prostate cancer.
- Ask him if he has had any recent unexpected weight loss.
- Take a sexual history for recent changes in sexuality, including libido or function.
- Ask about current or previous sexually transmitted infections, penile discharge, or scrotal pain or swelling.
What is a part of the physical assessment and what are the signs and symptoms are associated with prostate cancer?
- Most early cancers are diagnosed while the patient is having a routine physical examination or is being treated for benign prostatic hyperplasia (BPH).
- Gross blood in the urine (hematuria) is a common sign of late prostate cancer.
- Pain in the pelvis, hips, spine, or ribs, and swollen nodes indicate advanced disease that has spread.
- Take and record the patient’s weight because unexpected weight loss is also common when the disease is advanced.
- Prepare the patient for a digital rectal examination (DRE) by the health care provider.
- A prostate that is stony hard and with palpable irregularities or indurations is suspected to be malignant.
What is included in the psychosocial assessment?
- A diagnosis of any type of cancer causes fear and anxiety for most people.
- Some men, particularly African Americans, develop the disease in their 40s and 50s when they are putting their children through college, looking toward retirement in the coming years, and/or enjoying their middle years.
- Assess the reaction of the patient and family to the diagnosis.
- Men may describe their feelings as shock, fear, or anger, or a combination of these. Expect that patients usually go through the grieving process and may be in denial or depressed. Determine what support systems they have, such as family, friends, spiritual leaders, or community group support, to help them through diagnosis, treatment, and recovery.
- One of the biggest concerns the patient may have is his ability for sexual function after cancer treatment. Tell him that function will depend on the type of treatment he has. Common surgical techniques used today do not involve cutting the perineal nerves that are needed for an erection. – A dry climax may occur if the prostate is removed because it produces most of the fluid in the ejaculate.
- Refer the patient to his surgeon (urologist), sex therapist, or intimacy counselor if available.
What labs can be done?
- Prostate-specific antigen (PSA) is a glycoprotein produced by the prostate. If the patient and health care provider have agreed to screening, PSA analysis can be used as a screening test for prostate cancer. Because other prostate problems also increase the PSA level, it is not specifically diagnostic for cancer. However, it is commonly used in an effort to detect cancer early. If the test is performed, the specimen should be drawn before the DRE because the examination can cause an increase in PSA as a result of prostate irritation.
- Most authoritative sources agree that the normal blood level of PSA in men younger than 50 years is less than 2.5 ng/mL. PSA levels increase to as high as 6.5 ng/mL when men reach their 70s. African-American men between the ages of 50 and 59 have a slighter higher normal value than men who are Caucasian or Asian, but the reason for this difference is not known. However, levels greater than 4 ng/mL have been noted in more than 80% of men with prostate cancer.
- An elevated PSA level should decrease a few days after a prostatectomy for cancer. An increase in the PSA level several weeks after surgery may indicate that the disease has recurred.
- Because PSA is not absolutely specific to prostate cancer, another blood test, early prostate cancer antigen (EPCA-2), may be a serum marker for prostate cancer. It can reveal changes in the prostate gland early and is a very sensitive test.
What diagnostics are associated with prostate cancer?
- After assessments by DRE and PSA, most patients have a transrectal ultrasound (TRUS) of the prostate in an ambulatory care or imaging setting. Before the procedure, the health care provider uses lidocaine jelly on the ultrasound probe and/or injects lidocaine into the prostate gland to promote patient comfort. The provider inserts a small probe into the rectum and obtains a view of the prostate using sound waves. If prostate cancer is suspected, a biopsy is usually performed at that time to obtain an accurate diagnosis.
- After prostate cancer is diagnosed, the patient has additional imaging and blood studies to determine the extent of the disease. Common tests include lymph node biopsy, CT of the pelvis and abdomen, and MRI to assess the status of the pelvic and para-aortic lymph nodes. A radionuclide bone scan may be performed to detect metastatic bone disease. An enlarged liver or abnormal liver function study results indicate possible liver metastasis.
- Patients with advanced prostate cancer often have elevated levels of serum acid phosphatase. Most men with bone metastasis have elevated serum alkaline phosphatase levels and severe pain.
- As with any cancer, accurate staging and grading of prostate tumors guide monitoring and treatment planning during the course of the disease. Based on diagnostic assessment results, the cancer is staged, which can help to guide treatment choices. Table 67.2 shows how prostate cancer is staged.
What is the priority collaborative problem?
Potential for cancer metastasis due to lack of, or inadequate, treatment.
What is active surveillance and why is it done?
- Because prostate cancer is slow growing with late metastasis, older men who are asymptomatic and have other illnesses may choose observation without immediate active treatment, especially if the cancer is at an early stage. This option is known as active surveillance (AS). This form of treatment involves initial surveillance with active treatment only if the symptoms become bothersome. The average time from diagnosis to start of treatment is up to 10 years. During the AS period, men are monitored at regular intervals through DRE and PSA testing. Factors that are considered in choosing AS include potential side effects of treatment (e.g., urinary incontinence, erectile dysfunction), estimated life expectancy, the presence of comorbid medical conditions, and the risk for increased morbidity and mortality from not seeking active treatment.
- Patients who have very early–stage cancer of the prostate who choose AS require close follow-up by their primary health care provider. If obstruction occurs, a transurethral resection of the prostate (TURP) may be done.
- Specific management is based on the extent of the disease and the patient’s physical condition. The patient may undergo surgery for a biopsy (if not previously done), staging and removal of the tumor, or palliation to control the spread of disease or relieve distressing symptoms. As with AS, the health care provider and patient must weigh the benefits of treatment against potential adverse effects such as incontinence and erectile dysfunction (ED).
What are some nonsurgical management options?
- Radiation therapy. External or internal radiation therapy may be used in the treatment of prostate cancer or as salvage treatments when cancer recurs. It may also be done for palliation of the patient’s symptoms.
- External beam radiation therapy (EBRT) comes from a source outside the body. Patients are usually treated 5 days a week for a minimum of several weeks. EBRT can also be used to relieve pain from bone metastasis. Three-dimensional conformal radiation therapy (3D-CRT) can more accurately target prostate tissue and reduce damage to nearby organs and tissue. An advanced type of 3D-CRT radiation is intensity-modulated radiation therapy, which provides very high doses to the prostate. It is the most commonly used type of external beam radiation therapy for prostate cancer.
- Radiation proctitis may also develop but is less likely with 3D-CRT. Radiation that has irritated the rectum can cause urgency and cramping, which leads to rectal leakage. Teach him to report these symptoms to the health care provider. Like cystitis, this problem usually resolves 4 to 6 weeks after the treatment stops, although in rare cases it is permanent. If proctitis occurs, teach patients to limit spicy or fatty foods, caffeine, and dairy products.
- Low-dose brachytherapy is a type of internal radiation that is delivered by implanting low-dose radiation “seeds” (the size of a grain of rice) directly into the prostate gland. This treatment involves transrectal ultrasound, CT scans, or MRI, which are used to guide implantation of the seeds. These procedures are usually done on an ambulatory care basis under spinal or general anesthesia, and are the most cost-effective treatment for early-stage prostate cancer.
- Reassure the patient that the dose of radiation is low and that the radiation will not pose a hazard to him or others. Teach him that ED, urinary incontinence, and rectal problems do occur in a small percentage of cases. Fatigue is also common and may last for several months after the treatment stops.
- Drug therapy. Drug therapy may consist of either hormone therapy (androgen deprivation therapy [ADT]) or chemotherapy. Because most prostate tumors are hormone dependent, patients with extensive tumors or those with metastatic disease may be managed by androgen deprivation. Luteinizing hormone–releasing hormone (LHRH) agonists or antiandrogens can be used.
- LHRH agonists available in the United States include leuprolide, goserelin, histrelin, and triptorelin. These drugs first stimulate the pituitary gland to release luteinizing hormone (LH). After about 3 weeks, the pituitary gland is depleted of LH, which reduces testosterone production by the testes. Leuprolide is used most commonly for advanced prostate cancer with the goal of palliation
What should the nurse teach the patient regarding external beam radiation?
Teach patients that external beam radiation causes ED in many men well after the treatment is completed. Remind the patient that other complications from EBRT include urinary frequency, diarrhea, and acute radiation cystitis, which causes persistent pain and hematuria. Symptoms are usually mild to moderate and subside 6 weeks after treatment, although there is a rare chance that this will not go away. Teach the patient to avoid caffeine and continue drinking plenty of water and other fluids.
What are other nonsurgical management interventions?
- Antiandrogen drugs, also known as androgen deprivation therapy (ADT), work differently in that they block the body’s ability to use the available androgens. These drugs are the major treatment for metastatic disease. Examples include flutamide, bicalutamide, and nilutamide. They inhibit tumor progression by blocking the uptake of testicular and adrenal androgens at the prostate tumor site. Patients should be taught to follow closely with their health care provider and to undergo all laboratory testing as prescribed. These medications increase the risk for liver toxicity. Regular liver functions tests will be ordered at baseline, monthly during the first 4 months, and periodically thereafter.
- Antiandrogens may be used alone or in combination with LHRH agonists for total or maximal androgen blockade (hormone ablation).
Systemic chemotherapy may be an option for patients whose cancer has spread and for whom other therapies have not worked. For example, small cell prostate cancer is rare and is more responsive to chemotherapy than to hormone therapy. The goal of therapy is not curative; it is to slow the cancer’s growth so that the patient experiences a better quality of life.
What surgical interventions are associated with ;prostate cancer?
- For the LRP procedure, the patient is placed in lithotomy positioning with steep Trendelenburg. The urologist makes one or more small punctures or incisions into the abdomen. A laparoscope with a camera on the end is inserted through one of the incisions while other instruments are inserted into the other incisions. The robotic system may be used to control the movement of the instruments by a remote device. The prostate is removed along with nearby lymph nodes, but perineal nerves are not affected.
- The open radical prostatectomy can be performed via several surgical approaches, depending on the patient’s desired outcomes and the staging of the disease. The perineal and retropubic (nerve-sparing) approaches are most commonly used. The surgeon removes the entire prostate gland along with the prostatic capsule, the cuff at the bladder neck, the seminal vesicles, and the regional lymph nodes. The remaining urethra is connected to the bladder neck. The removal of tissue at the bladder neck allows the seminal fluid to travel upward into the bladder rather than down the urethral tract, resulting in retrograde ejaculation.
What preoperative care should be done?
Preoperative care depends on the type of surgery that will be done. Minimally invasive surgery (MIS) is most appropriate for localized prostate cancer and is used as a curative intervention. The most common procedure is the laparoscopic radical prostatectomy (LRP), often done with robotic assistance. Other procedures include transrectal high-intensity focused ultrasound (HIFU) and cryotherapy.
Patients who qualify for LRP must have a PSA less than 10 ng/mL and have had no previous hormone therapy or abdominal surgeries. Remind the patient that the advantages of this procedure over open surgery include:
- Decreased hospital stay (1 to 2 days)
- Minimal bleeding
- Smaller or no incisions and less scarring
- Less postoperative discomfort
- Decreased time for urinary catheter placement (usually removed on third postoperative day)
- Fewer complications
- Faster recovery and return to usual activities
- Nerve-sparing advantages